Skip to main content

Table 1 Patient characteristics

From: Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Number N (%)
Total 106 (100)
Age at diagnosis, median 57
FIGO stage  
I 8 (8)
II 8 (8)
III 76 (71)
IV 14 (13)
Histopathological subtype  
Serous* 94 (89)
Endometrioid 5 (4)
Serous + clear cell (mixed) 1 (1)
Transitiocellular carcinoma 1 (1)
Carcinosarcoma 1 (1)
Adenocarcinoma 1 (1)
Borderline (with invasive implants) 3 (3)
Number of prior chemotherapy regimens  
Median 4
Range 2 - 7
Interval from last chemotherapy regimens  
Median 1.8
Range 0.3-14.7 months
Bevacizumab infusions  
Median 4.5
Mean 7.1
Range 1 – 64**
≤ 2 cycles 22 (21)
≥ 9 cycles 29 (27)
Performance status at start of bevacizumab treatment  
0 40 (38)
1 52 (49)
2 13 (12)
3 1 (1)
Baseline VEGF, median (range) 504 (27–1847)
Baseline PDGF-AA, median (range) 2074.25 (207 – 5476.5)
Baseline PDGF-BB, median (range) 7789 (670–28487)
Baseline FGF2, median (range) 60 (8–234)
  1. * including primary peritoneal and fallopian cancer.
  2. ** still receiving bevacizumab.